The Experts below are selected from a list of 27 Experts worldwide ranked by ideXlab platform
James F. Lewis - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacotherapy for Prevention and Treatment of Acute Respiratory Distress Syndrome
Drugs, 2010Co-Authors: Karen J. Bosma, Ravi Taneja, James F. LewisAbstract:The acute respiratory distress syndrome (ARDS) arises from direct and indirect injury to the lungs and results in a life-threatening form of respiratory failure in a heterogeneous, critically ill patient population. Critical care technologies used to support patients with ARDS, including strategies for mechanical ventilation, have resulted in improved outcomes in the last decade. However, there is still a need for effective pharmacotherapies to treat ARDS, as mortality rates remain high. To date, no single pharmacotherapy has proven effective in decreasing mortality in adult patients with ARDS, although exogenous surfactant replacement has been shown to reduce mortality in the paediatric population with ARDS from direct causes. Several promising therapies are currently being investigated in preclinical and clinical trials for treatment of ARDS in its acute and subacute, exudative phases. These include exogenous surfactant therapy, β_2-adrenergic receptor agonists, antioxidants, immunomodulating agents and HMG-CoA reductase inhibitors (statins). Recent research has also focused on prevention of acute lung injury and acute respiratory distress in patients at risk. Drugs such as captopril, rosiglitazone and Incyclinide (COL-3), a tetracycline derivative, have shown promising results in animal models, but have not yet been tested clinically. Further research is needed to discover therapies to treat ARDS in its late, fibroproliferative phase. Given the vast number of negative clinical trials to date, it is unlikely that a single pharmacotherapy will effectively treat all patients with ARDS from differing causes. Future randomized controlled trials should target specific, more homogeneous subgroups of patients for single or combination therapy.
-
pharmacotherapy for prevention and treatment of acute respiratory distress syndrome current and experimental approaches
Drugs, 2010Co-Authors: Karen J. Bosma, Ravi Taneja, James F. LewisAbstract:The acute respiratory distress syndrome (ARDS) arises from direct and indirect injury to the lungs and results in a life-threatening form of respiratory failure in a heterogeneous, critically ill patient population. Critical care technologies used to support patients with ARDS, including strategies for mechanical ventilation, have resulted in improved outcomes in the last decade. However, there is still a need for effective pharmacotherapies to treat ARDS, as mortality rates remain high. To date, no single pharmacotherapy has proven effective in decreasing mortality in adult patients with ARDS, although exogenous surfactant replacement has been shown to reduce mortality in the paediatric population with ARDS from direct causes. Several promising therapies are currently being investigated in preclinical and clinical trials for treatment of ARDS in its acute and subacute, exudative phases. These include exogenous surfactant therapy, β2-adrenergic receptor agonists, antioxidants, immunomodulating agents and HMG-CoA reductase inhibitors (statins). Recent research has also focused on prevention of acute lung injury and acute respiratory distress in patients at risk. Drugs such as captopril, rosiglitazone and Incyclinide (COL-3), a tetracycline derivative, have shown promising results in animal models, but have not yet been tested clinically. Further research is needed to discover therapies to treat ARDS in its late, fibroproliferative phase. Given the vast number of negative clinical trials to date, it is unlikely that a single pharmacotherapy will effectively treat all patients with ARDS from differing causes. Future randomized controlled trials should target specific, more homogeneous subgroups of patients for single or combination therapy.
Karen J. Bosma - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacotherapy for Prevention and Treatment of Acute Respiratory Distress Syndrome
Drugs, 2010Co-Authors: Karen J. Bosma, Ravi Taneja, James F. LewisAbstract:The acute respiratory distress syndrome (ARDS) arises from direct and indirect injury to the lungs and results in a life-threatening form of respiratory failure in a heterogeneous, critically ill patient population. Critical care technologies used to support patients with ARDS, including strategies for mechanical ventilation, have resulted in improved outcomes in the last decade. However, there is still a need for effective pharmacotherapies to treat ARDS, as mortality rates remain high. To date, no single pharmacotherapy has proven effective in decreasing mortality in adult patients with ARDS, although exogenous surfactant replacement has been shown to reduce mortality in the paediatric population with ARDS from direct causes. Several promising therapies are currently being investigated in preclinical and clinical trials for treatment of ARDS in its acute and subacute, exudative phases. These include exogenous surfactant therapy, β_2-adrenergic receptor agonists, antioxidants, immunomodulating agents and HMG-CoA reductase inhibitors (statins). Recent research has also focused on prevention of acute lung injury and acute respiratory distress in patients at risk. Drugs such as captopril, rosiglitazone and Incyclinide (COL-3), a tetracycline derivative, have shown promising results in animal models, but have not yet been tested clinically. Further research is needed to discover therapies to treat ARDS in its late, fibroproliferative phase. Given the vast number of negative clinical trials to date, it is unlikely that a single pharmacotherapy will effectively treat all patients with ARDS from differing causes. Future randomized controlled trials should target specific, more homogeneous subgroups of patients for single or combination therapy.
-
pharmacotherapy for prevention and treatment of acute respiratory distress syndrome current and experimental approaches
Drugs, 2010Co-Authors: Karen J. Bosma, Ravi Taneja, James F. LewisAbstract:The acute respiratory distress syndrome (ARDS) arises from direct and indirect injury to the lungs and results in a life-threatening form of respiratory failure in a heterogeneous, critically ill patient population. Critical care technologies used to support patients with ARDS, including strategies for mechanical ventilation, have resulted in improved outcomes in the last decade. However, there is still a need for effective pharmacotherapies to treat ARDS, as mortality rates remain high. To date, no single pharmacotherapy has proven effective in decreasing mortality in adult patients with ARDS, although exogenous surfactant replacement has been shown to reduce mortality in the paediatric population with ARDS from direct causes. Several promising therapies are currently being investigated in preclinical and clinical trials for treatment of ARDS in its acute and subacute, exudative phases. These include exogenous surfactant therapy, β2-adrenergic receptor agonists, antioxidants, immunomodulating agents and HMG-CoA reductase inhibitors (statins). Recent research has also focused on prevention of acute lung injury and acute respiratory distress in patients at risk. Drugs such as captopril, rosiglitazone and Incyclinide (COL-3), a tetracycline derivative, have shown promising results in animal models, but have not yet been tested clinically. Further research is needed to discover therapies to treat ARDS in its late, fibroproliferative phase. Given the vast number of negative clinical trials to date, it is unlikely that a single pharmacotherapy will effectively treat all patients with ARDS from differing causes. Future randomized controlled trials should target specific, more homogeneous subgroups of patients for single or combination therapy.
Ravi Taneja - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacotherapy for Prevention and Treatment of Acute Respiratory Distress Syndrome
Drugs, 2010Co-Authors: Karen J. Bosma, Ravi Taneja, James F. LewisAbstract:The acute respiratory distress syndrome (ARDS) arises from direct and indirect injury to the lungs and results in a life-threatening form of respiratory failure in a heterogeneous, critically ill patient population. Critical care technologies used to support patients with ARDS, including strategies for mechanical ventilation, have resulted in improved outcomes in the last decade. However, there is still a need for effective pharmacotherapies to treat ARDS, as mortality rates remain high. To date, no single pharmacotherapy has proven effective in decreasing mortality in adult patients with ARDS, although exogenous surfactant replacement has been shown to reduce mortality in the paediatric population with ARDS from direct causes. Several promising therapies are currently being investigated in preclinical and clinical trials for treatment of ARDS in its acute and subacute, exudative phases. These include exogenous surfactant therapy, β_2-adrenergic receptor agonists, antioxidants, immunomodulating agents and HMG-CoA reductase inhibitors (statins). Recent research has also focused on prevention of acute lung injury and acute respiratory distress in patients at risk. Drugs such as captopril, rosiglitazone and Incyclinide (COL-3), a tetracycline derivative, have shown promising results in animal models, but have not yet been tested clinically. Further research is needed to discover therapies to treat ARDS in its late, fibroproliferative phase. Given the vast number of negative clinical trials to date, it is unlikely that a single pharmacotherapy will effectively treat all patients with ARDS from differing causes. Future randomized controlled trials should target specific, more homogeneous subgroups of patients for single or combination therapy.
-
pharmacotherapy for prevention and treatment of acute respiratory distress syndrome current and experimental approaches
Drugs, 2010Co-Authors: Karen J. Bosma, Ravi Taneja, James F. LewisAbstract:The acute respiratory distress syndrome (ARDS) arises from direct and indirect injury to the lungs and results in a life-threatening form of respiratory failure in a heterogeneous, critically ill patient population. Critical care technologies used to support patients with ARDS, including strategies for mechanical ventilation, have resulted in improved outcomes in the last decade. However, there is still a need for effective pharmacotherapies to treat ARDS, as mortality rates remain high. To date, no single pharmacotherapy has proven effective in decreasing mortality in adult patients with ARDS, although exogenous surfactant replacement has been shown to reduce mortality in the paediatric population with ARDS from direct causes. Several promising therapies are currently being investigated in preclinical and clinical trials for treatment of ARDS in its acute and subacute, exudative phases. These include exogenous surfactant therapy, β2-adrenergic receptor agonists, antioxidants, immunomodulating agents and HMG-CoA reductase inhibitors (statins). Recent research has also focused on prevention of acute lung injury and acute respiratory distress in patients at risk. Drugs such as captopril, rosiglitazone and Incyclinide (COL-3), a tetracycline derivative, have shown promising results in animal models, but have not yet been tested clinically. Further research is needed to discover therapies to treat ARDS in its late, fibroproliferative phase. Given the vast number of negative clinical trials to date, it is unlikely that a single pharmacotherapy will effectively treat all patients with ARDS from differing causes. Future randomized controlled trials should target specific, more homogeneous subgroups of patients for single or combination therapy.
Vieira, Giovanni Modesto - One of the best experts on this subject based on the ideXlab platform.
-
The effect of tetracycline modified and simvastatin on relapse of tooth movement in periodontal ligament of the rats
2015Co-Authors: Vieira, Giovanni ModestoAbstract:Introdução: A recidiva dentária após o tratamento ortodôntico tem um enorme impacto na clínica ortodôntica, em especial a recidiva imediata, afetando os benefícios da terapêutica ortodôntica. Os dispositivos de contenção fixa não permitem a inibição da recidiva dentária, devido à ocorrência da remodelação óssea ativa após a remoção dos aparelhos ortodônticos, que dependem das enzimas metaloproteinases para a sua presença. Algumas drogas podem atuar na inibição das metaloproteinases e inibir a recidiva dentária. Objetivos: O objetivo deste estudo foi de avaliar o efeito da tetraciclina modificada quimicamente CMT-3 (inciclinida) e sinvastatina na recidiva da movimentação dentária em ratos através de um novo método por micro CT, bem como a correlação da densidade mineral óssea com a recidiva dentária. Material e Métodos: Quarenta ratos adultos e machos, da variedade Wistar, com massa de 354 +/- 33 gramas, foram separados em três grupos, sendo um grupo controle com 10 animais e dois grupos experimentais com 15 animais, e tiveram molas de aço inoxidável instaladas no primeiro molar superior esquerdo. Os molares murinos foram movimentados em direção mesial durante 18 dias (desprezando a movimentação dos incisivos em direção distal), e após a remoção das molas, foram aplicadas por gavagem oral: 30mg/kg de inciclinida e 5mg/kg de sinvastatina nos dois grupos experimentais, e carboximetilcelulose a 0,5% no grupo controle, durante 20 dias. Foram realizadas três aquisições microtomográficas: a primeira aquisição após a instalação das molas, a segunda aquisição após 18 dias de movimentação dentária, e a terceira aquisição após a remoção das molas no décimo oitavo dia e término da instituição do regime de tratamento das drogas durante vinte dias, no trigésimo oitavo dia. A recidiva dentária foi visualizada com o auxílio de microtomógrafo CT, e as 120 imagens reconstruídas e escolhidas por intermédio dos softwares N-Recon- 1.6.9.4, e Data Viewer 1.5.0.0 (referentes às três aquisições microtomográficas com 40 animais dos três grupos), tiveram as suas guias de mensuração realizadas (correspondentes a duas retas tangentes as face de maior convexidade: distal do primeiro molar superior esquerdo e mesial do segundo molar, perpendiculares ao plano oclusal destes dentes, e mensuradas pela união destas duas retas) e aferida pelo software Image ProR plus 5.1, e comparadas por Kruskal Walis e teste pós- hoc de Dunn através de SPSS-22. Após o sacrifício dos animais, foi mensurada a densidade mineral óssea e a unidade Hounsfield por micro-CT, do osso alveolar adjacente à raiz mesial e distal do primeiro molar movimentado (em uma área ROI circular de 60 x 60 pixels previamente escolhida) através do software CT Analyser 1.13, e analisada por ANOVA com pós-hoc de Tukey no SPSS-22. A correlação entre a recidiva dentária e a densidade mineral óssea foi analisada por teste de Spearman. Resultados: O presente trabalhou permitiu uma melhor acurácia da mensuração da recidiva dentária, em relação aos métodos tradicionais de moldagem, transferência de dados e aferição. A recidiva foi menor no grupo experimental da inciclinida em relação ao grupo controle (p=0,048), e foi encontrada significância estatística (p=0,007) entre a droga inciclinida e o grupo controle. A droga sinvastatina não inibiu a recidiva dentária com a posologia empregada. Ocorreu uma diminuição da densidade mineral óssea e da unidade Hounsfield adjacente à raiz mesial e distal no grupo da sinvastatina durante a recidiva dentária. A densidade mineral óssea e a unidade Hounsfield diminuíram na região óssea adjacente à raiz distal, e aumentaram na região óssea adjacente á raiz mesial do grupo da inciclinida durante a recidiva dentária. Não foi achada correlação entre a densidade mineral óssea e a recidiva dentária no osso alveolar da raiz mesial (p=-0,282) e do osso alveolar da raiz distal (p=0,061). Conclusões: A droga CMT-3 inciclinida inibiu a recidiva da movimentação dentária em ratos. A droga sinvastatina não inibiu a recidiva dentária em ratos. ______________________________________________________________________________________________ ABSTRACTIntroduction: the dental orthodontic treatment after recurrence has a huge impact on orthodontic clinic, in particular the immediate relapse, affecting the benefits of orthodontic therapy. Fixed containment devices do not allow dental recurrence inhibition due to the occurrence of active bone remodeling upon removal of orthodontic appliances, which depend on the enzymes for their presence. Metalloproteinases Some drugs may act on inhibition of Metalloproteinases and inhibit dental recurrence. Objectives: the objective of this study was to evaluate the effect of chemically modified tetracycline CMT-3 (Incyclinide) and simvastatin on relapse of tooth movement in rats using a new method for micro CT as well as the correlation of bone mineral density with tooth recurrence. Material and methods: forty rats adults and males, of variety, with mass of Wistar 354 +/- 33 grams, were divided into three groups, being a control group with 10 animals and two experimental groups with 15 animals, and stainless steel springs were installed on the upper left first molars. Murinos molars were moved toward mesial during 18 days (disregarding the movement of incisors in distal direction), and after removing the springs, were applied by oral gavage: 30 mg/kg of Incyclinide and 5 mg/kg of simvastatin in two experimental groups, and carboxymethylcellulose the 0.5 in the control group, for 20 days. Three were carried out microtomography acquisitions: the first acquisition after installation of the springs, the second acquisition after 18 days of tooth movement, and the third acquisition after removal of the springs in the eighteenth day and ending the institution of drug treatment regimen for twenty days, in the thirty-eighth day. Dental recurrence was visualized with the aid of microtomography CT, and the 120 images reconstructed and chosen through the software N-Recon-1.6.9.4, and Data Viewer 1.5.0.0 (related to three microtomography acquisitions with 40 animals of three groups), had their measurement guides carried out (corresponding to the two tangent lines the face of greatest convexity: the left upper first molars distal and mesial of the second molar, perpendiculars to the occlusal plane of these teeth, and measured by the union of these two straight) and checked by the software Image ProR plus 5.1, and compared by Kruskal and Post-hoc test valid Dunn through SPSS-22. After the sacrifice of animals was measured bone mineral density and Hounsfield unit for micro-CT, the alveolar bone adjacent to the mesial and distal root of the busy first molars (in an area 60 x 60 circular ROI pixels previously chosen) through software CT Analyzer 1.13, and analyzed by ANOVA with Post-hoc Turkey in SPSS-22. The correlation between dental recurrence and bone mineral density was analyzed by Spearman test. Results: the present worked allowed a better measurement of dental recurrence, compared to traditional methods of molding, data transfers and scouting. The recurrence was lower in the experimental group of Incyclinide in relation to the control group (p= 0,048), and statistical significance was found (p= 0,007) between the drug Incyclinide and the control group. The drug simvastatin inhibited not dental recurrence with the dosage employed. There has been a decrease in bone mineral density and Hounsfield unit adjacent to the mesial and distal root in the simvastatin group during dental recurrence. Bone mineral density and Hounsfield unit decreased in the region adjacent to the distal root, and have increased in the region adjacent to the mesial root of the group of the Incyclinide during the dental relapse. No correlation was found between bone mineral density and recurrence in dental alveolar bone of the mesial root (p= -0,282) and the alveolar bone of the distal root (p= 0,061). Conclusions: the drug CMT-3 Incyclinide inhibited the relapse of tooth movement in rats. The drug simvastatin inhibited not dental recurrence in rats
-
The effect of tetracycline modified and simvastatin on relapse of tooth movement in periodontal ligament of the rats
'Biblioteca Central da UNB', 2015Co-Authors: Vieira, Giovanni ModestoAbstract:Tese (doutorado)—Universidade de Brasília, Faculdade de Medicina, Pós-graduação em Ciências Médicas, 2015.Introdução: A recidiva dentária após o tratamento ortodôntico tem um enorme impacto na clínica ortodôntica, em especial a recidiva imediata, afetando os benefícios da terapêutica ortodôntica. Os dispositivos de contenção fixa não permitem a inibição da recidiva dentária, devido à ocorrência da remodelação óssea ativa após a remoção dos aparelhos ortodônticos, que dependem das enzimas metaloproteinases para a sua presença. Algumas drogas podem atuar na inibição das metaloproteinases e inibir a recidiva dentária. Objetivos: O objetivo deste estudo foi de avaliar o efeito da tetraciclina modificada quimicamente CMT-3 (inciclinida) e sinvastatina na recidiva da movimentação dentária em ratos através de um novo método por micro CT, bem como a correlação da densidade mineral óssea com a recidiva dentária. Material e Métodos: Quarenta ratos adultos e machos, da variedade Wistar, com massa de 354 +/- 33 gramas, foram separados em três grupos, sendo um grupo controle com 10 animais e dois grupos experimentais com 15 animais, e tiveram molas de aço inoxidável instaladas no primeiro molar superior esquerdo. Os molares murinos foram movimentados em direção mesial durante 18 dias (desprezando a movimentação dos incisivos em direção distal), e após a remoção das molas, foram aplicadas por gavagem oral: 30mg/kg de inciclinida e 5mg/kg de sinvastatina nos dois grupos experimentais, e carboximetilcelulose a 0,5% no grupo controle, durante 20 dias. Foram realizadas três aquisições microtomográficas: a primeira aquisição após a instalação das molas, a segunda aquisição após 18 dias de movimentação dentária, e a terceira aquisição após a remoção das molas no décimo oitavo dia e término da instituição do regime de tratamento das drogas durante vinte dias, no trigésimo oitavo dia. A recidiva dentária foi visualizada com o auxílio de microtomógrafo CT, e as 120 imagens reconstruídas e escolhidas por intermédio dos softwares N-Recon- 1.6.9.4, e Data Viewer 1.5.0.0 (referentes às três aquisições microtomográficas com 40 animais dos três grupos), tiveram as suas guias de mensuração realizadas (correspondentes a duas retas tangentes as face de maior convexidade: distal do primeiro molar superior esquerdo e mesial do segundo molar, perpendiculares ao plano oclusal destes dentes, e mensuradas pela união destas duas retas) e aferida pelo software Image ProR plus 5.1, e comparadas por Kruskal Walis e teste pós- hoc de Dunn através de SPSS-22. Após o sacrifício dos animais, foi mensurada a densidade mineral óssea e a unidade Hounsfield por micro-CT, do osso alveolar adjacente à raiz mesial e distal do primeiro molar movimentado (em uma área ROI circular de 60 x 60 pixels previamente escolhida) através do software CT Analyser 1.13, e analisada por ANOVA com pós-hoc de Tukey no SPSS-22. A correlação entre a recidiva dentária e a densidade mineral óssea foi analisada por teste de Spearman. Resultados: O presente trabalhou permitiu uma melhor acurácia da mensuração da recidiva dentária, em relação aos métodos tradicionais de moldagem, transferência de dados e aferição. A recidiva foi menor no grupo experimental da inciclinida em relação ao grupo controle (p=0,048), e foi encontrada significância estatística (p=0,007) entre a droga inciclinida e o grupo controle. A droga sinvastatina não inibiu a recidiva dentária com a posologia empregada. Ocorreu uma diminuição da densidade mineral óssea e da unidade Hounsfield adjacente à raiz mesial e distal no grupo da sinvastatina durante a recidiva dentária. A densidade mineral óssea e a unidade Hounsfield diminuíram na região óssea adjacente à raiz distal, e aumentaram na região óssea adjacente á raiz mesial do grupo da inciclinida durante a recidiva dentária. Não foi achada correlação entre a densidade mineral óssea e a recidiva dentária no osso alveolar da raiz mesial (p=-0,282) e do osso alveolar da raiz distal (p=0,061). Conclusões: A droga CMT-3 inciclinida inibiu a recidiva da movimentação dentária em ratos. A droga sinvastatina não inibiu a recidiva dentária em ratos.Introduction: the dental orthodontic treatment after recurrence has a huge impact on orthodontic clinic, in particular the immediate relapse, affecting the benefits of orthodontic therapy. Fixed containment devices do not allow dental recurrence inhibition due to the occurrence of active bone remodeling upon removal of orthodontic appliances, which depend on the enzymes for their presence. Metalloproteinases Some drugs may act on inhibition of Metalloproteinases and inhibit dental recurrence. Objectives: the objective of this study was to evaluate the effect of chemically modified tetracycline CMT-3 (Incyclinide) and simvastatin on relapse of tooth movement in rats using a new method for micro CT as well as the correlation of bone mineral density with tooth recurrence. Material and methods: forty rats adults and males, of variety, with mass of Wistar 354 +/- 33 grams, were divided into three groups, being a control group with 10 animals and two experimental groups with 15 animals, and stainless steel springs were installed on the upper left first molars. Murinos molars were moved toward mesial during 18 days (disregarding the movement of incisors in distal direction), and after removing the springs, were applied by oral gavage: 30 mg/kg of Incyclinide and 5 mg/kg of simvastatin in two experimental groups, and carboxymethylcellulose the 0.5 in the control group, for 20 days. Three were carried out microtomography acquisitions: the first acquisition after installation of the springs, the second acquisition after 18 days of tooth movement, and the third acquisition after removal of the springs in the eighteenth day and ending the institution of drug treatment regimen for twenty days, in the thirty-eighth day. Dental recurrence was visualized with the aid of microtomography CT, and the 120 images reconstructed and chosen through the software N-Recon-1.6.9.4, and Data Viewer 1.5.0.0 (related to three microtomography acquisitions with 40 animals of three groups), had their measurement guides carried out (corresponding to the two tangent lines the face of greatest convexity: the left upper first molars distal and mesial of the second molar, perpendiculars to the occlusal plane of these teeth, and measured by the union of these two straight) and checked by the software Image ProR plus 5.1, and compared by Kruskal and Post-hoc test valid Dunn through SPSS-22. After the sacrifice of animals was measured bone mineral density and Hounsfield unit for micro-CT, the alveolar bone adjacent to the mesial and distal root of the busy first molars (in an area 60 x 60 circular ROI pixels previously chosen) through software CT Analyzer 1.13, and analyzed by ANOVA with Post-hoc Turkey in SPSS-22. The correlation between dental recurrence and bone mineral density was analyzed by Spearman test. Results: the present worked allowed a better measurement of dental recurrence, compared to traditional methods of molding, data transfers and scouting. The recurrence was lower in the experimental group of Incyclinide in relation to the control group (p= 0,048), and statistical significance was found (p= 0,007) between the drug Incyclinide and the control group. The drug simvastatin inhibited not dental recurrence with the dosage employed. There has been a decrease in bone mineral density and Hounsfield unit adjacent to the mesial and distal root in the simvastatin group during dental recurrence. Bone mineral density and Hounsfield unit decreased in the region adjacent to the distal root, and have increased in the region adjacent to the mesial root of the group of the Incyclinide during the dental relapse. No correlation was found between bone mineral density and recurrence in dental alveolar bone of the mesial root (p= -0,282) and the alveolar bone of the distal root (p= 0,061). Conclusions: the drug CMT-3 Incyclinide inhibited the relapse of tooth movement in rats. The drug simvastatin inhibited not dental recurrence in rats
J R Prous - One of the best experts on this subject based on the ideXlab platform.
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology, 2007Co-Authors: M Bayes, X Rabasseda, J R ProusAbstract:Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issues focuses on the following selection of drugs: (-)-Epigallocatechin gallate, 101M, AAV-AADC, AGN-201904-Z; Agomelatine, AN-0128, AN-2690, Arginine butyrate, Asenapine maleate; Belinostat, Bortezomib, BQ-123, BQ-788; Bucindolol hydrochloride; Certolizumab pegol; Dasatinib, Denosumab, Desvenlafaxine succinate; Ecogramostim, Esomeprazole magnesium; Homoharringtonine; huN901-DM1, Hyaluronic acid; Incyclinide; L-Arginine hydrochloride; Mepolizumab; Nematode anticoagulant protein c2, Nilotinib; Oblimersen sodium; R-115866, Raltegravir potassium, Retapamulin, Romidepsin, Rusalatide acetate; Sarcosine, SCIO-469, Soblidotin, Sorivudine; Tilarginine hydrochloride, Tipifarnib; Uracil; Vildagliptin.
